Marino Garcia Sells 166,000 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock

Key Points

• CEO Marino Garcia sold 166,000 Dianthus Therapeutics shares at an average price of $108.11, generating approximately $17.95 million. The transaction reduced his direct ownership by 71.77% to 65,292 shares.
• Dianthus shares closed at $108.92, near their 12-month high of $114.55, with a market capitalization of approximately $5.95 billion. The company recently reported a quarterly loss of $0.90 per share, missing estimates by $0.05.
• Institutional investors own 47.53% of the stock, while analysts maintain a generally positive outlook: the shares have a consensus “Moderate Buy” rating and an average price target of $124.27.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) CEO Marino Garcia sold 166,000 shares of Dianthus Therapeutics stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the completion of the transaction, the chief executive officer directly owned 65,292 shares in the company, valued at approximately $7,058,718.12. The trade was a 71.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Dianthus Therapeutics Price Performance

Shares of Dianthus Therapeutics stock traded down $1.00 on Friday, hitting $108.92. The company had a trading volume of 570,177 shares, compared to its average volume of 974,445. The stock has a 50-day moving average of $94.40 and a 200-day moving average of $80.45. Dianthus Therapeutics, Inc. has a twelve month low of $18.08 and a twelve month high of $114.55. The firm has a market capitalization of $5.95 billion, a P/E ratio of -26.25 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.05). The company had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. Equities analysts predict that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of large investors have recently modified their holdings of DNTH. BlackRock Inc. acquired a new position in Dianthus Therapeutics during the second quarter valued at approximately $401,990,000. Wellington Management Group LLP grew its stake in Dianthus Therapeutics by 3,366.9% in the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company's stock valued at $101,431,000 after purchasing an additional 2,503,311 shares in the last quarter. Vestal Point Capital LP increased its position in shares of Dianthus Therapeutics by 88.2% during the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company's stock worth $59,616,000 after purchasing an additional 1,499,931 shares during the last quarter. State Street Corp increased its position in shares of Dianthus Therapeutics by 124.7% during the 4th quarter. State Street Corp now owns 1,507,619 shares of the company's stock worth $62,129,000 after purchasing an additional 836,571 shares during the last quarter. Finally, Polar Capital Holdings Plc bought a new stake in shares of Dianthus Therapeutics during the 3rd quarter worth approximately $29,434,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently commented on DNTH shares. Wall Street Zen upgraded Dianthus Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, May 9th. Wolfe Research reissued an "outperform" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Truist Financial boosted their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a "buy" rating in a research note on Thursday. Raymond James Financial reaffirmed a "strong-buy" rating and set a $131.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday. Finally, Guggenheim reaffirmed a "buy" rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $124.27.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source